Electrophysiologic Abnormalities in AL (Primary) Amyloidosis With Cardiac Involvement  by Reisinger, Johann et al.
Electrophysiologic Abnormalities in AL (Primary) Amyloidosis With
Cardiac Involvement
JOHANN REISINGER, MD, SIMON W. DUBREY, MD, MICHAEL LAVALLEY, PHD,*
MARTHA SKINNER, MD,* RODNEY H. FALK, MD, FACC
Boston, Massachusetts
Objectives. This study sought to determine the spectrum of
electrophysiologic abnormalities found in patients with cardiac
involvement due to AL (primary) amyloidosis and to evaluate the
prognostic implications, particularly in relation to subsequent
sudden death.
Background. Only case reports, but no series of invasive
electrophysiologic studies, exist in patients with cardiac AL.
Methods. Twenty-five patients with biopsy-proven AL and car-
diac involvement underwent standard invasive electrophysiologic
studies.
Results. The function of the sinus and the atrioventricular node
was preserved in most patients, but the infra-His (HV) conduction
times were usually abnormal. The mean (6SD) HV interval for
the 25 patients was 79 6 18 ms (range 50 to 110), and 23 patients
(92%) had an abnormally prolonged interval (>55 ms). Marked
HV prolongation (>280 ms) occurred in 12 patients, 6 of whom had
an interval >2100 ms. Among the 23 patients who died during
follow-up, HV prolongation was the sole independent predictor of
sudden death by multivariate analysis (p 5 0.05).
Conclusions. Patients with cardiac AL are prone to disease in
the His-Purkinje system. Prolongation of the HV interval is
common and may not be suspected from the surface electrocar-
diogram in the presence of a narrow QRS complex. These patients
have a high prevalence of sudden death, of which the HV interval
is an independent predictor. The association of HV prolongation
and sudden death is probably multifactorial, representing either a
marker of severe myocardial infiltration with an increased pro-
pensity to lethal ventricular arrhythmias or electromechanical
dissociation, or indicating severe conduction system disease even-
tually leading to complete atrioventricular block and bradycardic
death.
(J Am Coll Cardiol 1997;30:1046–51)
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AL amyloidosis (formerly known as primary amyloidosis) is a
multisystem disease caused by plasma cell dyscrasia and char-
acterized by the extracellular deposition of fibrils composed of
immunoglobulin light chains within various organs. Clinical
evidence of cardiac involvement, usually in the form of con-
gestive heart failure, is present in ;30% to 50% of patients (1).
The 12-lead electrocardiogram (ECG) reflects the generalized
infiltrative nature of this disease with low voltage in the limb
leads, pseudoinfarction patterns in the anterior precordial or
inferior limb leads, or both, and abnormalities of conduction
such as fascicular block or atrioventricular block of varying
degree (2–4). When cardiac involvement is present, death is
frequently sudden, accounting for 30% to 50% of all cardiac
deaths (5). No adequate method for predicting sudden death
exists in amyloid heart disease.
Histologic examination reveals that the amyloid fibrils may
infiltrate the cardiac conduction system and may preferentially
involve the His-Purkinje system (6,7). The widespread involve-
ment of the myocardium and the conduction system implies
that several different mechanisms may be responsible for
sudden death in cardiac amyloidosis—namely, ventricular ar-
rhythmias, atrioventricular (AV) block and acute electrome-
chanical dissociation. Only two case reports have described
electrophysiologic findings in AL and both showed prolonged
infra-His (HV) conduction times (8,9).
The aims of the present study were therefore twofold: to
determine the spectrum of electrophysiologic abnormalities
found in cardiac AL and to evaluate the prognostic implica-
tions of any demonstrable abnormalities, particularly in rela-
tion to subsequent sudden death.
Methods
Study group. The study group consisted of 25 patients (18
men and 7 women, mean age 57.1 6 9.0 years) with docu-
mented AL involving the heart; these patients were referred to
Boston University Medical Center for evaluation of their
disease. The diagnosis of systemic amyloidosis was confirmed
by the occurrence of amyloid fibril deposits with the charac-
teristic green birefringence after Congo red staining of biopsy
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tissue. Most patients had multiple biopsies taken, but the sites
of biopsy from which the initial diagnosis was made were the
heart in five patients, the rectum in five patients, the kidney in
four patients, subcutaneous abdominal fat in three patients,
the tongue in two patients, the submandibular lymph node in
two patients and the stomach, bone marrow, lung and liver in
one patient each. The diagnosis of AL was made in all 25
patients by evidence of plasma cell dyscrasia or by identifica-
tion of an immunoglobulin light chain in their amyloid depos-
its, or both (10). All patients had a complete history and
physical examination, a 12-lead ECG, serum electrolyte mea-
surements, chest X-ray film and two-dimensional and Doppler
echocardiograms. Twenty-four-hour Holter recordings were
performed in 22 patients; signal-averaged ECGs were analyzed
in 17 patients and not studied in 8 patients (due to a QRS
complex duration $120 ms on the surface ECG in 5 patients).
Cardiac amyloidosis was defined as otherwise unexplained
low voltage on the ECG and/or an echocardiogram with wall
thickening (mean left ventricular wall thickness .1.1 cm) in
the absence of hypertension or significant valvular disease,
with a tissue biopsy from any organ staining positive for the
presence of amyloid deposits (11). We did not require an
endomyocardial biopsy because, in such cases, cardiac biopsy
almost invariably shows myocardial amyloid (12). Heart failure
was considered present on physical examination in patients
with jugular venous distention or with clinical or radiologic
evidence of pulmonary venous congestion. Low voltage was
defined as a mean QRS voltage amplitude of all ECG limb
leads of ,0.5 mV. A pseudoinfarction pattern was defined as
pathologic Q waves (width $40 ms) or QS waves in the
anteroseptal or inferior leads, or both, in the absence of a
documented history of myocardial infarction. Intraventricular
conduction disturbances were classified according to current
guidelines (13). A late potential on the signal-averaged ECG
was defined as present according to currently accepted stan-
dards (14).
Electrophysiologic studies. Nine patients were studied be-
cause of clinical indications (unexplained syncope in six, pre-
syncope in two and sustained spontaneous ventricular tachy-
cardia [VT] in one). The remaining 16 patients underwent
electrophysiologic study as part of a prospective risk assess-
ment. After written, informed consent was obtained, all pa-
tients underwent electrophysiologic study (approved by the
local Institutional Review Board) in a nonsedated, fasting
state. All antiarrhythmic drugs were discontinued at least 48 h
before the study. No patient had taken amiodarone during the
past 6 months. Three electrode catheters were positioned one
each in the right atrium, the His bundle and the right ventricle.
Three surface ECG leads and the bipolar intracardiac electro-
grams (filtered at 40 to 500 Hz) were recorded simultaneously
at a paper speed of 100 mm/s. His bundle electrograms were
recorded with multipolar catheters with a 0.5-cm interelec-
trode distance. In an attempt to avoid recordings of right
bundle branch potentials, the catheter was withdrawn proxi-
mally until both large atrial and ventricular electrograms were
displayed, suggesting an AV location of recording electrodes.
Validation of His potentials was attempted in most of the
patients, using the responses to (single and coupled) atrial
pacing. The supra-His (AH) conduction time was taken from
the earliest reproducible rapid deflection of the atrial electro-
gram in the His bundle recording to the onset of the His
deflection. His bundle potential duration (H) was taken from
the earliest onset of the His deflection to its end, and the HV
interval from the beginning of the His bundle deflection to the
earliest onset of ventricular activation recorded from multiple
surface ECG leads or the intracardiac electrograms. Normal
conduction intervals were defined as follows (15): AH 60 to
125 ms, HV 35 to 55 ms and H 10 to 25 ms. Standard
electrophysiologic methods (15) were used to determine the
Wenckebach cycle length, the effective refractory period of the
AV node, sinus node recovery time (SNRT) and maximal
corrected sinus node recovery time (cSNRT). A programmable
stimulator was used to deliver rectangular pulses 2 ms in
duration at twice the diastolic threshold (threshold always
#1.3 mA in the right atrium and #1 mA in the right ventricle).
Programmed ventricular stimulation was performed using sin-
gle and double extrastimuli introduced after an 8-beat drive
train at cycle lengths of 600 and 400 ms, and diastole was
scanned in 10-ms decrements. A third extrastimulus was
delivered only at a basic drive cycle length of 400 ms. The end
point of ventricular stimulation was the reproducible initiation
of sustained monomorphic VT, defined as VT lasting .30 s or
requiring termination because of hemodynamic collapse. Ven-
tricular tachycardia was considered monomorphic if the QRS
configuration was constant and the cycle length was .200 ms.
The induction of polymorphic VT or ventricular fibrillation in
these patients was not considered as a valid end point, but
rather as a nonspecific response (16).
Survival was measured from the time of the electrophysi-
ologic study until death or to heart transplantation in the two
patients who underwent this procedure. Our analyses are
based on the assumption that heart transplantation is an
equivalent of dying of congestive heart failure, because both
patients were hospitalized and terminally ill due to refractory
heart failure at the time of their heart transplantation. Sudden
death was defined as natural unexpected death that occurred
either instantaneously (including during sleep) or within 1 h
after the onset of symptoms.
Abbreviations and Acronyms
AH 5 supra-His conduction time
AL 5 amyloidosis, light chain (primary)
AV 5 atrioventricular
cSNRT 5 corrected sinus node recovery time
ECG 5 electrocardiogram, electrocardiographic
H 5 His bundle potential duration
HV 5 infra-His conduction time
SNRT 5 sinus node recovery time
VT 5 ventricular tachycardia
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Statistical analysis. Continuous data are presented as
mean value 6 SD. Overall survival data are presented as
median values. Univariate statistical analyses were done by the
chi-square test for proportions or t tests for intergroup differ-
ences of continuous variables; median survival times were
analyzed by the Mann-Whitney U test. A p value #0.05 was
considered significant; 95% confidence intervals are given if
appropriate. Multivariate analysis (logistic regression with
stepwise selection of predictor variables) was performed using
the Statistical Analysis System Software (version 6.11, SAS
Institute Inc.), including all variables presenting p values #0.15
by univariate analysis.
Results
Surface ECG. The 12-lead ECG was abnormal in all 25
patients (Table 1).
Electrophysiologic findings (Table 1). Electrophysiologic
testing revealed normal maximal cSNRT in all but three
patients. The effective refractory period of the AV node
determined by atrial extrastimuli delivered during a drive cycle
length of 600 ms was not abnormally prolonged in any patient.
For the 25 patients, the mean AH interval was 121 6 33 ms
(range 70 to 210). Nine patients had an AH interval greater
than the upper limit of 125 ms. Measurements of the HV
intervals contrasted markedly with the findings in the proximal
conduction system. The mean HV interval for the 25 patients
was 79 6 18 ms (range 50 to 110), and 23 patients had an
abnormally prolonged interval (.55 ms). Marked HV prolon-
gation ($80 ms) occurred in 12 patients, six of whom had an
interval $100 ms. Rapid incremental atrial pacing resulted in
block below the His bundle in only one patient. Ventricular
stimulation induced monomorphic VT in four patients. In
three patients this was induced by double extrastimuli and
required overdrive pacing or cardioversion for termination. All
three of these patients had a positive late potential. The fourth
patient had a self-terminating 40-beat run of monomorphic VT
induced by triple extrastimuli. His signal-averaged ECG was
normal.
Relation between surface ECG and electrophysiologic find-
ings. First-degree AV block on the ECG occurred in 13
patients, 8 of whom had a prolonged AH interval, but all 13
had HV prolongation. The mean HV interval in the 20 patients
with a QRS duration ,120 ms was 77 6 18 ms, whereas it was
88 6 17 ms in the five patients with a QRS duration $120 ms
(p 5 0.28). Nine of our 20 patients with a QRS complex
,120 ms in duration showed first-degree AV block on the
surface ECG. Fourteen of these 20 patients showed abnormal
HV conduction, with an HV interval .55 ms and ,80 ms in
five patients and a markedly ($80 ms) prolonged HV interval
in nine patients (Fig. 1). In five patients, prolonged HV
conduction (first-degree block in the His bundle with a total
duration of the His bundle deflection of $30 ms, often with a
notched or fragmented deflection) was present. There was no
significant relation between the HV interval and either a
history of syncope or presyncope, septal thickness or left
ventricular ejection fraction.
Results of signal-averaged ECG. The signal-averaged
ECGs were recorded in 22 patients and analyzed in the 17
patients with a surface ECG QRS duration ,120 ms. Ventric-
ular late potentials were present in seven and absent in 10
patients. The mean HV interval duration in patients with late
potentials was 84 6 19 ms, and in those without late potentials,
72 6 19 ms (p 5 0.24).
Therapeutic management. Two patients underwent pace-
maker insertion and one patient prophylactic implantation of a
cardioverter-defibrillator. These procedures were performed
at the discretion of the referring physician on the basis of
neurologic symptoms (syncope in all three patients) and elec-
trophysiologic abnormalities (significant infranodal disease in
one patient, combination of sinus node dysfunction and infra-
nodal disease in one patient and induction of ventricular
fibrillation in one patient).
Follow-up. Twenty-three of the original 25 patients died or
underwent heart transplantation during follow-up, with a
median duration of survival of 3 months (range 0.5 to 50). The
most common cause of death was sudden death, which oc-
curred in 10 patients, including all three patients with perma-
nent pacemakers or implantable cardioverter-defibrillators.
Seven patients died from congestive heart failure and two
patients underwent heart transplantation due to refractory
heart failure. Four patients died from noncardiac causes
(hepatic failure in two and renal insufficiency in two). The
median time to death or heart transplantation was 2 months in
patients with sudden death, compared with 5 months in those
with a nonsudden death or those undergoing heart transplan-
tation (Mann-Whitney U test, p 5 0.08).
Predictors of death. Univariate and multivariate analyses
were performed in the 23 patients who died or underwent
heart transplantation to evaluate any predictive factors. Uni-
variate analysis revealed a significant association between a
markedly prolonged HV interval ($80 ms) and the occurrence
Table 1. Clinical and Electrophysiologic Characteristics of 25
Study Patients
Male/female 18/7 (72%/28%)
History of syncope or presyncope 9 (36%)
PR interval .200 ms 13 (52%)
Pathologic Q waves 16 (64%)
LAFB 6 (24%)
LPFB 2 (8%)
QRS duration $120 ms 5 (20%)
RBBB 2 (8%)
LBBB 2 (8%)
IVCD 1 (4%)
Mean maximal cSNRT (ms) 401 6 237
Mean AH interval (ms) 121 6 33
Mean HV interval (ms) 79 6 18
Data presented are number (%) of patients or mean value 6 SD. cSNRT 5
corrected sinus node recovery time; IVCD 5 nonspecific intraventricular
conduction delay; LAFB 5 left anterior fascicular block; LBBB 5 left bundle
branch block; LPFB 5 left posterior fascicular block; RBBB 5 right bundle
branch block.
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of sudden death (chi-square, p 5 0.024). The mean HV
interval in patients with sudden death was 86 6 14 ms,
compared with a mean HV interval of 71 6 18 ms in those who
died nonsuddenly or underwent heart transplantation (two-
tailed t test, p 5 0.038). Figure 2 shows the number of patients
who had sudden death, nonsudden death or heart transplan-
tation within each category of HV interval duration. There was
also a significant association between a history of syncope or
presyncope and the occurrence of sudden death by univariate
analysis (chi-square, p 5 0.026) (Table 2). Only four patients
had inducible monomorphic VT, two of whom died suddenly
and two from noncardiac complications of AL. In a multivar-
iate model that examined the HV interval, history of syncope
or presyncope, presence of a late potential and age, only a
prolongation of the HV interval was an independent predictor
of sudden death (p 5 0.05), with an odds ratio of 2.26 for a
10-ms increase in the HV interval.
Discussion
In this series of patients with cardiac AL, AV node conduc-
tion was borderline or within normal limits, whereas distur-
bances in the His-Purkinje system were common and marked
prolongation of the HV interval was often seen, even in the
presence of a narrow QRS complex. Moreover, we found a
significant association between HV interval prolongation and
the occurrence of sudden death among those patients who died
during follow-up.
Pathophysiology of HV prolongation. The finding of HV
prolongation in the majority of these patients, even when the
QRS complex was relatively narrow, implies that the distal
conduction system is extensively infiltrated. The rarity of
bundle branch block on the surface ECG is in contrast to
electrophysiologic studies in other forms of heart disease, in
which a prolonged HV interval of this degree is almost always
associated with an abnormally wide QRS complex (17,18). In
nonamyloid heart disease, it is postulated that the coexistence
of HV prolongation and bundle branch block reflects a non-
homogeneous involvement of the bundle branches by the
underlying pathologic process (18,19). Our finding may reflect
the widespread, generalized infiltration seen in amyloid heart
disease and described in pathologic studies (2,8). This typically
homogeneous involvement of both bundle branches may ex-
plain the rare occurrence of a complete unilateral bundle
Figure 1. A, Twelve-lead ECG showing low voltage in
the limb leads, a pseudoinfarction pattern in lead V2, a
borderline PR interval of 200 ms and a narrow QRS
complex (QRS duration 100 ms). B, His-bundle electro-
cardiogram (HBE) of the same patient showing a nor-
mal AH interval of 100 ms, but a prolonged H duration
of 30 ms and a markedly prolonged HV interval of
90 ms. A 5 atrial electrogram; H 5 His potential;
RVA 5 right ventricular apex; V 5 ventricular electro-
gram.
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branch block in these patients. An equivalent conduction delay
in both bundle branches would result in a narrow QRS
complex but a prolonged HV interval.
Interaction of HV prolongation and sudden death. Cardiac
AL is a rapidly fatal disease. Although we found a significant
association between HV prolongation and subsequent sudden
death, this finding does not necessarily imply that death is due
to asystole resulting from complete heart block. We have
previously shown (20) that an abnormal signal-averaged ECG
is a predictor of sudden death in a larger series of patients with
AL—a finding interpreted as indicating a role for tachyar-
rhythmias in sudden death. We do not believe these two
findings are contradictory but would suggest that the associa-
tion between HV prolongation and sudden death is multifac-
torial. In some patients, HV prolongation may represent a
marker of more severe myocardial infiltration, possibly in-
creasing the propensity to sudden death due to lethal ventric-
ular arrhythmias or to acute electromechanical dissociation. In
other patients, it may be a marker of severe conduction system
disease indicative of a propensity to complete heart block and
bradycardic death. At present, we have no way to differentiate
the significance of a markedly prolonged HV interval in an
individual patient with AL.
Prolongation of the HV interval was common even in
patients with AL without a history of syncope or presyncope.
Thus, caution should be applied in interpreting this finding in
a patient with AL who presents with syncope. This is anecdot-
ally demonstrated in the two patients who died suddenly
despite appropriately functioning permanent pacemakers in-
serted because of syncope and HV prolongation. Earlier
studies of patients with prolonged HV intervals and bifascicu-
lar block (21,22) found a markedly prolonged HV interval to
be predictive of sudden death. However, the cause of sudden
death, when documented, was more often due to ventricular
tachyarrhythmias than to complete AV block (23,24). Conse-
quently, we would urge caution in using the HV interval as a
guide to pacemaker implantation in amyloid heart disease.
Inducibility of ventricular arrhythmias and sudden death.
In patients with coronary artery disease and a previous myo-
cardial infarction, the lack of inducibility of VT has been
proposed as a beneficial prognostic marker in relation to
subsequent sudden death (25). In contrast, failure to induce
VT does not imply a benign outcome in patients with nonisch-
emic cardiomyopathies (26). Similarly, the lack of inducibility
of sustained monomorphic VT in the majority of our patients
did not portend a favorable prognosis in terms of sudden
death. Thus, in cardiac AL, as in other forms of nonischemic
cardiomyopathies, noninducibility has little prognostic value.
Study limitations. Amyloidosis is a rare disease, thereby
limiting the size of our study group. Nevertheless, despite our
cohort size, we were able to show consistent abnormalities and
significant associations.
Our patients had light-chain associated amyloidosis and
these data should not be extrapolated to patients with familial
amyloidosis, in whom a high prevalence of conduction distur-
bances has been shown and a requirement for permanent
pacing due to high degree AV block is relatively frequent
(27–29).
Conclusions. This study demonstrates that patients with
cardiac AL are prone to disease in the His-Purkinje system.
Prolongation of the HV interval is common and may not be
suspected from the surface ECG in the presence of a narrow
QRS complex. Patients with cardiac AL have a high prevalence
Figure 2. Bar graph showing number of patients who had sudden
death (solid bars) or nonsudden death (hatched bars) or those
undergoing heart transplantation (open bars) within each category of
HV interval duration.
Table 2. Univariate Analysis of Characteristics of All 23 Patients
Who Died During Follow-Up
Sudden Death
Group
(n 5 10)
Nonsudden Death
Group*
(n 5 13)
p
Value
Age at time of EP study
(yr)
52.6 6 10.1 60.1 6 7.3 0.066
Male 6 (60%) 10 (77%) 0.38
HV interval (ms) 86 6 14 71 6 18 0.038
HV interval $80 ms 7 (70%) 3 (23%) 0.024
LAFB or LPFB 3 (30%) 4 (31%) 0.97
QRS duration $120 ms 2 (20%) 3 (23%) 0.86
Positive SAECG† 4/6 (67%) 3/10 (30%) 0.15
Inducibility of
monomorphic VT
2 (20%) 2 (15%) 0.77
History of syncope or
presyncope
6 (60%) 2 (15%) 0.026
Septal thickness (cm) 1.6 6 0.3 1.6 6 0.3 0.94
LVEF (%) 49 6 13 48 6 12 0.82
Heart failure 9 (90%) 12 (92%) 0.85
*The nonsudden death group includes both patients who underwent heart
transplantation. †Signal-averaged electrocardiographic records were analyzed in
only 16 patients who died subsequently. Data are presented as mean value 6 SD
or number (%) of patients. EP 5 electrophysiologic; LVEF 5 left ventricular
ejection fraction; SAECG 5 signal-averaged electrocardiogram; VT 5 ventric-
ular tachycardia; other abbreviations as in Table 1.
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of sudden death, of which the HV interval is an independent
predictor. Prolongation of the HV interval may serve as a
marker for the propensity to lethal tachyarrhythmias, brady-
arrhythmias or acute electromechanical dissociation.
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